ANDA 70954, held by Watson Labs. Doxepin Hydrochloride.
As of Nov 16, 2026, ANDA 70954 (Doxepin Hydrochloride), held by Watson Labs, was not approved, with 0 approved supplements and 0 published complete response letters.
| Product | Active ingredient | Marketing |
|---|---|---|
| Doxepin HydrochlorideEQ 50MG BASE ยท capsule;oral | Doxepin Hydrochloride | Discontinued |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters